# Independent nutrition change review — September 12, 2026

Reviewer: operative-review agent, independent of the author of these changes. This review concerns the introduced changes to the six evaluation pages below. It is a bounded peer review, not a new full audit of every legacy statement or a clinician sign-off.

## Result

No introduced blocking clinical error was identified in the reviewed changes. No source files were edited by this reviewer. The author's per-page source-access limits in `reports/2026-09-11/full-site-review/evaluation.json` remain applicable; this report does not convert abstract access into a full-paper review.

## Material checks

| Page | Independently checked points |
| --- | --- |
| Copper | Replacement regimens are attributed separately: ASMBS oral 3–8 mg/day and severe-deficiency IV 2–4 mg/day are not interchangeable with ESPEN's separate 4–8 mg/day IV regimen. Prophylaxis is separated from treatment. |
| Folate | CDC recurrence prevention uses 4,000 micrograms/day starting one month before conception through the first three months of pregnancy. The AAN/AES/SMFM epilepsy recommendation is at least 0.4 mg/day, without inventing a universal higher dose. |
| Vitamin B12 | NICE thresholds of under 180 and 180–350 ng/L, cause-specific lifelong IM treatment, and oral doses of at least 1 mg/day when used for other malabsorption are correctly distinguished. OB12's oral maintenance was 1 mg **weekly** after eight weeks of daily treatment; it does not establish year-long noninferiority of daily oral treatment. |
| Thiamine | Suspected/established Wernicke treatment is separated from ASAM withdrawal prophylaxis. The cited UK acute-hospital guideline specifies IV 300–500 mg three times daily for 3–5 days, with further daily treatment if symptoms persist. Emergency glucose treatment must not be delayed. |
| Vitamin D | The AACE replacement regimen is scoped to its osteoporosis population. The Pittas pooled three-year absolute reduction of 3.3 percentage points implies an NNT of approximately 30, and is not the result of D2d alone. Prevention recommendations are not universal serum targets or deficiency-treatment regimens. |
| Vitamin A | AQUASOL A is for IM use, with the product's 100,000-unit three-day loading phase followed by 50,000 units/day for two weeks; this is not an IV regimen. FDA's current iPLEDGE update delays the modifications to November 15, 2026. The 2025 Cochrane diagnostic sensitivity estimate is presented with its wide interval and source-access limitations. |

The changed text and references were read for all six pages. The final vitamin-A toxicity and reproductive-safety text was also read directly after the initial diff output required a separate chunk. Guideline and label checks were targeted to the points above; no claim is made that this reviewer independently read every source listed by the author.

## Primary sources used for this independent check

- [ASMBS micronutrient guideline](https://asmbs.org/wp-content/uploads/2017/06/ASMBS-Nutritional-Guidelines-2016-Update.pdf), relevant replacement tables; [ESPEN practical micronutrient guideline](https://www.espen.org/files/ESPEN-Guidelines/ESPEN-practical-short-micronutrient-guideline.pdf), copper recommendations.
- [CDC folic acid guidance](https://www.cdc.gov/folic-acid/about/index.html); [AAN/AES/SMFM practice guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC11175651/), folate recommendation.
- [NICE NG239](https://www.nice.org.uk/guidance/ng239/chapter/Recommendations), diagnostic and cause-specific treatment recommendations; [OB12 primary report](https://pmc.ncbi.nlm.nih.gov/articles/PMC7440823/), dosing and noninferiority conclusion.
- [UK acute-hospital alcohol guideline](https://www.gov.uk/guidance/clinical-guidelines-for-alcohol-treatment/16-alcohol-care-in-acute-hospitals), section 16.9.4; [ASAM alcohol withdrawal guideline](https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf), thiamine prophylaxis recommendations.
- [Pittas 2023 individual-participant meta-analysis](https://d2dstudy.org/wp-content/uploads/2024/02/2023-Pittas-AnnInternMed-vitamin-D-and-t2DM-IPD.pdf), absolute effect and study population; AACE 2020 vitamin-D section in the primary guideline PDF cited in the author's ledger.
- [AQUASOL A label](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=1abd66eb-6ac8-4a9e-a609-251e46ea1a27&type=pdf); [FDA iPLEDGE update](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems); [Cochrane 2025 diagnostic review](https://doi.org/10.1002/14651858.CD013742.pub2), primary abstract only.

## Reviewed source snapshots

All files are under `docs/02-evaluation/laboratory-studies/nutritional-assessment/`. These hashes identify the source content at report creation; any subsequent substantive change needs its own review.

| File | SHA-256 |
| --- | --- |
| copper.mdx | `54de0046d8113107cbcfa569286405399ce7e5a3e82d7f3752ffa108ba620672` |
| folate.mdx | `fede7fc50938a820ef41daa8d7f8e12629084545226275730e3caad79f8dd013` |
| vitamin-b12.mdx | `fbd2d35a8de9527fc66a52819213ee6d7a8aeffc1bc63b627cd9ffb03f212178` |
| thiamine.mdx | `80d80fd794bc0a0f66e2372ad08f5e5d976bbbd83040b24b0a69eb09a750b647` |
| vitamin-d.mdx | `a520bdc3b9b97237792f24b202511d0d699e43c7b6727804a76fd4cd98a5abfe` |
| vitamin-a.mdx | `4b5e0548449ff6d6790b2d34225dc8e535b9115b5bc32ecb641ff64aae547a6a` |
